Browsing Breast Cancer Research by author "Bruna Cabot, Alejandra"
Now showing items 1-3 of 3
-
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
Gris-Oliver, A; Palafox, M; Monserrat, L; Brasó-Maristany, F; Òdena, A; et al. (AMER ASSOC CANCER RESEARCH, 2020-07-15)PURPOSE: AZD5363/capivasertib is a pan-AKT catalytic inhibitor with promising activity in combination with paclitaxel in triple-negative metastatic breast cancer harboring PI3K/AKT-pathway alterations and in estrogen ... -
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
Palafox, M; Monserrat, L; Bellet, M; Villacampa, G; Gonzalez-Perez, A; et al. (NATURE PORTFOLIO, 2022-09-07)CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these tumors are ... -
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
Serra, V; Wang, AT; Castroviejo-Bermejo, M; Polanska, UM; Palafox, M; et al. (AMER ASSOC CANCER RESEARCH, 2022-10-14)PURPOSE: PARP inhibitors (PARPi) induce synthetic lethality in homologous recombination repair (HRR)-deficient tumors and are used to treat breast, ovarian, pancreatic, and prostate cancers. Multiple PARPi resistance ...